TRICAPITAL

Ryboquin Ltd. is a virtual pharmaceutical company based in Selkirk, United Kingdom, focused on developing and commercializing oncology therapies. Incorporated in 2013, the company aims to transform under-developed intellectual property into effective treatments for cancer patients. Its primary product in the pipeline is ECP-102, a tumor apoptosis enhancer that aims to improve the efficacy of chemotherapy across various cancer types. Ryboquin utilizes advanced technologies, including nanotechnology, to optimize its gene therapies and enhance the overall effectiveness of cancer treatment, making them more accessible and affordable for patients and healthcare professionals worldwide.

FINDRA is a Scottish brand specializing in high-performance outdoor and adventure clothing for women. The company focuses on designing stylish, versatile, and sustainable apparel made from Italian merino wool, which offers natural wicking properties. By providing high-quality clothing that balances performance and aesthetics, FINDRA encourages women to embrace outdoor activities and lead healthier, more active lifestyles. The brand's mission is to inspire women to pursue adventure without compromising on style or functionality, helping them to become better versions of themselves. Through its e-commerce platform, FINDRA promotes a commitment to sustainability while catering to the needs of adventurous women.

Ryboquin Ltd. is a virtual pharmaceutical company based in Selkirk, United Kingdom, focused on developing and commercializing oncology therapies. Incorporated in 2013, the company aims to transform under-developed intellectual property into effective treatments for cancer patients. Its primary product in the pipeline is ECP-102, a tumor apoptosis enhancer that aims to improve the efficacy of chemotherapy across various cancer types. Ryboquin utilizes advanced technologies, including nanotechnology, to optimize its gene therapies and enhance the overall effectiveness of cancer treatment, making them more accessible and affordable for patients and healthcare professionals worldwide.

Inquisitive Systems Ltd. is a data protection software company based in Edinburgh, United Kingdom, established in 2008 as a spin-out from Edinburgh Napier University. Founded by Dr. Jamie Graves and Professor Bill Buchanan, the company aims to become a leader in information security software. Inquisitive Systems developed its core technology, foxDNATM, during Dr. Graves' postgraduate research focused on enhancing digital forensic investigations. The software is designed to protect intellectual property from security breaches, analyze relevant data, provide alerts, and monitor forensic user activity. After securing a grant from Scottish Enterprise, the company began commercial operations in 2010, focusing on delivering innovative solutions to address growing cybersecurity challenges.

pureLiFi Ltd. is a light communications technology company based in Edinburgh, United Kingdom, that specializes in developing Li-Fi, a visible light communications technology. By utilizing the visible light spectrum instead of traditional radio frequencies, pureLiFi enables wireless data communication. The company offers various products, including Li-1st, which allows customers to develop and test VLC applications; Li-Flame, a secure wireless network solution; and the Li-Fire Platform, which supports wireless communications through light. Its technology is applicable in diverse fields such as smart lighting, healthcare, aviation, and location-based services, addressing issues like RF spectrum relief and enhancing mobile connectivity. Originally founded as pureVLC Ltd. in 2012, the company rebranded in 2013 to reflect its focus on Li-Fi solutions.

Sphinx Medical Ltd. is a company located in Bellshill, Scotland, United Kingdom. It develops the artificial sphincter Flow-Secure, which has been sold in Europe for 9 years. It is an innovative device that enables the treatment of severe Male Urinary Incontinence.

Biopta Ltd. is a contract research organization based in Glasgow, United Kingdom, specializing in human tissue-based services for the pharmaceutical industry. Founded in 2002, the company utilizes ethically donated residual human tissue from surgeries to predict drug activity prior to clinical trials. Biopta provides a range of services, including laboratory and comparative pharmacology, clinical biopsies, and both in-vitro and ex-vivo techniques. Their expertise spans several therapeutic areas, offering services related to cardiac, vascular, respiratory, gastrointestinal, human absorption, skin, and genitourinary functions. In addition, Biopta maintains a catalogue of human functional tissue assays, which includes various standard assays. The organization operates laboratories in Glasgow and Maryland and functions as a subsidiary of ReproCELL, Inc. since December 2015.

Touch Bionics Limited, established in 2003 and headquartered in Livingston, United Kingdom, specializes in developing and distributing advanced upper-limb prosthetics for individuals with upper limb deficiencies. The company's product portfolio includes the i-LIMB Hand, a multi-articulating bionic hand; Prosthetic Digits, self-contained fingers for partial hand patients; and ProDigits, a bionic finger solution for those missing fingers. Touch Bionics serves customers in various regions worldwide, including North America, Europe, Asia, Australia, and South Africa. As of April 2016, the company operates as a subsidiary of Össur hf.